Page last updated: 2024-09-04

mdl 100240 and Cirrhosis

mdl 100240 has been researched along with Cirrhosis in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Belloni, AS; Guidolin, D; Nussdorfer, GG; Pessina, AC; Rossi, GP; Seccia, TM; Sticchi, D	1

Other Studies

1 other study(ies) available for mdl 100240 and Cirrhosis

Article	Year
The renal antifibrotic effects of angiotensin-converting enzyme inhibition involve bradykinin B2 receptor activation in angiotensin II-dependent hypertension. Journal of hypertension, 2006, Volume: 24, Issue:7 Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Animals, Genetically Modified; Atrial Natriuretic Factor; Benzazepines; Creatinine; Fibrosis; Hypertension; Kidney; Male; Neprilysin; Pyridines; Ramipril; Rats; Receptor, Bradykinin B2	2006

Article

Year

The renal antifibrotic effects of angiotensin-converting enzyme inhibition involve bradykinin B2 receptor activation in angiotensin II-dependent hypertension.

Journal of hypertension, 2006, Volume: 24, Issue:7

Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Animals, Genetically Modified; Atrial Natriuretic Factor; Benzazepines; Creatinine; Fibrosis; Hypertension; Kidney; Male; Neprilysin; Pyridines; Ramipril; Rats; Receptor, Bradykinin B2

2006